Back to top
more

Merck Co., Inc. (MRK)

(Real Time Quote from BATS)

$80.45 USD

80.45
1,397,700

-0.60 (-0.74%)

Updated Aug 10, 2020 11:38 AM ET

3-Hold of 5     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value B Growth B Momentum A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

Sweta Killa

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Zacks Equity Research

Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress

Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.

Kinjel Shah

Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus

Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.

Zacks Equity Research

Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

Exelixis (EXEL) beats on earnings and sales in the second quarter.

Zacks Equity Research

Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss

Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.

Zacks Equity Research

Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates

Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.

Zacks Equity Research

Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up

Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.

Zacks Equity Research

Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

Zacks Equity Research

Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates

Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.

Benjamin Rains

3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio

Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...

Sweta Killa

5 Growth ETFs & Stocks to Ride the Market Rally

Growth investing has taken the lead over value and is likely to stay given a slew of reasons.

Zacks Equity Research

Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

Zacks Equity Research

Company News for Aug 3, 2020

Companies In The News Are: MRK, CVX, NOK, CHD.

Zacks Equity Research

Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

Zacks Equity Research

Merck (MRK) Beats on Q2 Earnings, Misses Sales, Ups View

Merck (MRK) increases earnings and sales guidance for the year, which pushes shares up in pre-market trading.

Zacks Equity Research

Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales

Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.

Mark Vickery

More Earnings, Data Following Big Tech Q2 Blowout: XOM, MRK, CAT & More

Markets finish out a busy week in the heart of Q2 earnings season with plenty of other leaders across a spectrum of industries, plus a few new economic reports.

Zacks Equity Research

Earnings & Economic Data Deluge

Earnings & Economic Data Deluge

Zacks Equity Research

Merck (MRK) Q2 Earnings Beat Estimates

Merck (MRK) delivered earnings and revenue surprises of 20.18% and -0.42%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AstraZeneca (AZN) Q2 Earnings & Sales Beat, Increase Y/Y

AstraZeneca (AZN) comes up with better-than expected Q2 results. It maintains its financial outlook for the year. Stock up.

Zacks Equity Research

How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? (Revised)

Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's(MRK) performance when it reports second-quarter earnings.

Zacks Equity Research

Pfizer (PFE) Q2 Earnings Top, Sales Hurt by Coronavirus, View Up

Pfizer (PFE) beats estimates for earnings while missing the same for sales. It slightly raises its financial outlook for the year.

Zacks Equity Research

How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings?

Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports second-quarter earnings.

Sweta Killa

What Lies Ahead for Healthcare ETFs in Q2 Earnings?

The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.